Validation of the Skindex-17 Quality of Life Assessment Instrument for a Brazilian Population

Overview

Journal An Bras Dermatol

Specialty Dermatology

Date 2020 Dec 7

PMID 33281012

Citations 2

Authors

Marilia Formentini Scotton Jorge

Ioana Bittencourt Mourao

Camila Fernandes Pollo

Ticiane Dionizio de Sousa

Silmara Meneguin

Helio Amante Miot

Affiliations

Soon will be listed here.

Abstract

Background: Health-related quality of life assesses how diseases affect the daily life of people; there are several generic instruments for this assessment in dermatology. Skindex was created in 1996; it is a multidimensional instrument, aiming to encompass some psychological and social aspects not yet addressed by other questionnaires. Among its versions (Skindex-29, 16, and 17), Skindex-17 had not been validated in Brazil.

Objectives: To validate Skindex-17 for use in Brazilians with dermatological diseases.

Methods: This was a methodological, cross-sectional, and prospective study of 217 patients attended at the Dermatology Service Outpatient Clinic, Faculdade de Medicina de Botucatu - Universidade Estadual Paulista (Botucatu, SP, Brazil), from December 2017 to September 2019. The following were evaluated: content validity, filling time, internal consistency, dimensional structure, concurrent validity (DLQI), temporal stability, and responsiveness.

Results: The sample consisted of 71% women, mean age (SD) of 45 (16) years; phototypes II-IV accounted for 95% of the cases. Cronbach's alpha coefficients were 0.82 and 0.93 for the symptoms and psychosocial conditions, respectively. A high correlation was observed with the DLQI score: symptoms (rho = 0.69) and psychosocial conditions (rho = 0.75). The instrument's two-dimensional structure was confirmed through confirmatory factor analysis. Temporal stability (ICC > 0.9) and score responsiveness (p ≤ 0.02) were verified. The instrument was shown to be feasible in clinical practice due to the content validation performed by professionals and patients, as well as the low time spent completing it (< 5 min).

Study Limitations: Single-center study, with patients exclusively from the public healthcare system.

Conclusions: Skindex-17 was shown to be a valid and consistent instrument for assessing quality of life among patients with dermatological diseases, in Brazil. Its two-dimensional structure was confirmed.

Citing Articles

The Dermatology Life Quality Index (DLQI) used as the benchmark in validation of 101 quality-of-life instruments: A systematic review.

Vyas J, Johns J, Abdelrazik Y, Ali F, Ingram J, Salek S J Eur Acad Dermatol Venereol. 2024; 39(3):631-679.

PMID: 39269008 PMC: 11851266. DOI: 10.1111/jdv.20321.

Ghezzi G, Costanzo A, Borroni R J Clin Med. 2024; 13(16).

PMID: 39200764 PMC: 11354811. DOI: 10.3390/jcm13164623.

Analysis of data with dependent measures in clinical and experimental studies.

Miot H J Vasc Bras. 2023; 22:e20220150.

PMID: 37333755 PMC: 10275643. DOI: 10.1590/1677-5449.202201502.

References

Miot H . Correlation analysis in clinical and experimental studies. J Vasc Bras. 2019; 17(4):275-279. PMC: 6375260. DOI: 10.1590/1677-5449.174118. View

Chren M, Lasek R, Quinn L, Mostow E, Zyzanski S . Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1996; 107(5):707-13. DOI: 10.1111/1523-1747.ep12365600. View

Liang S, Cohen J, Ho R . Psoriasis and suicidality: A review of the literature. Dermatol Ther. 2018; 32(1):e12771. DOI: 10.1111/dth.12771. View

Carcano C, de Oliveira C, Paiva B, Paiva C . The Brazilian version of Skindex-16 is a valid and reliable instrument to assess the health-related quality of life of patients with skin diseases. PLoS One. 2018; 13(3):e0194492. PMC: 5864026. DOI: 10.1371/journal.pone.0194492. View

Chren M, Lasek R, Flocke S, Zyzanski S . Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997; 133(11):1433-40. View

Vasquez D, Aguirre D, Sanclemente G . Construct validity and responsiveness of the Colombian version of Skindex-29. Br J Dermatol. 2019; 181(4):770-777. DOI: 10.1111/bjd.17742. View

Chren M, Lasek R, Sahay A, Sands L . Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001; 5(2):105-10. DOI: 10.1007/BF02737863. View

Rapp S, Feldman S, Exum M, Fleischer Jr A, Reboussin D . Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999; 41(3 Pt 1):401-7. DOI: 10.1016/s0190-9622(99)70112-x. View

Twiss J, Meads D, Preston E, Crawford S, McKenna S . Can we rely on the Dermatology Life Quality Index as a measure of the impact of psoriasis or atopic dermatitis?. J Invest Dermatol. 2011; 132(1):76-84. DOI: 10.1038/jid.2011.238. View

10.

Seidl E, Zannon C . [Quality of life and health: conceptual and methodological issues]. Cad Saude Publica. 2004; 20(2):580-8. DOI: 10.1590/s0102-311x2004000200027. View

11.

Mokkink L, Terwee C, Patrick D, Alonso J, Stratford P, Knol D . The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res. 2010; 19(4):539-49. PMC: 2852520. DOI: 10.1007/s11136-010-9606-8. View

12.

Tavakol M, Dennick R . Making sense of Cronbach's alpha. Int J Med Educ. 2016; 2:53-55. PMC: 4205511. DOI: 10.5116/ijme.4dfb.8dfd. View

13.

Miot H, Penna G, Ramos A, Penna M, Schmidt S, Barbosa Luz F . Profile of dermatological consultations in Brazil (2018). An Bras Dermatol. 2018; 93(6):916-928. PMC: 6256211. DOI: 10.1590/abd1806-4841.20188802. View

14.

Arnone M, Takahashi M, de Carvalho A, Bernardo W, Bressan A, Ramos A . Diagnostic and therapeutic guidelines for plaque psoriasis - Brazilian Society of Dermatology. An Bras Dermatol. 2019; 94(2 Suppl 1):76-107. PMC: 6544036. DOI: 10.1590/abd1806-4841.2019940211. View

15.

Barbieri J, Gelfand J . Influence of "Not Relevant" Responses on the Dermatology Life Quality Index (DLQI) for Patients With Psoriasis in the United States. JAMA Dermatol. 2019; 155(6):743-745. PMC: 6533805. DOI: 10.1001/jamadermatol.2018.5655. View

16.

Halioua B, Beumont M, Lunel F . Quality of life in dermatology. Int J Dermatol. 2000; 39(11):801-6. DOI: 10.1046/j.1365-4362.2000.00793.x. View

17.

Nijsten T, Sampogna F, Chren M, Abeni D . Testing and reducing skindex-29 using Rasch analysis: Skindex-17. J Invest Dermatol. 2006; 126(6):1244-50. DOI: 10.1038/sj.jid.5700212. View

18.

Paula H, Haddad A, Weiss M, Dini G, Ferreira L . Translation, cultural adaptation, and validation of the American Skindex-29 quality of life index. An Bras Dermatol. 2014; 89(4):600-7. PMC: 4148274. DOI: 10.1590/abd1806-4841.20142453. View

19.

Shimizu G, Wedy G, Schaefer L, Muller Ramos P, Miot H . Translation into Portuguese language (Brazil), transcultural adaptation and validation of the quality of life questionnaire in female pattern hair loss (WAA-QoL-BP). An Bras Dermatol. 2018; 93(5):701-706. PMC: 6106656. DOI: 10.1590/abd1806-4841.20187452. View

20.

Sanchez J, Zakzuk J, Cardona R . Evaluation of a Guidelines-Based Approach to the Treatment of Chronic Spontaneous Urticaria. J Allergy Clin Immunol Pract. 2017; 6(1):177-182.e1. DOI: 10.1016/j.jaip.2017.06.002. View